Oramed Pharmaceuticals Inc. (ORMP) announced that the FDA has cleared the company's Investigational New Drug application for ORMD-0801, its oral insulin capsule.
Oramed's ORMD-0801 is an orally ingestible insulin capsule indicated for the early stages of type 2 diabetes, when it can still slow the rate of degeneration of the disease by providing additional insulin to the body and allowing pancreatic respite.
For comments and feedback: editorial@rttnews.com